What is claimed is:

1. An aqueous pharmaceutical formulation comprising:

a VEGF receptor fusion protein at a concentration of at least 100 mg/ml;

L-arginine;

a sugar;

a histidine-based buffer; and

a surfactant;

wherein the formulation has a pH of 5.0 to 6.8.

2. The formulation of claim 1 which is suitable for intravitreal administration.

3. The formulation of any one of claims 1-2 further comprising sodium sulfate, sodium thiocyanate, glycine, NaCl, sodium aspartate, and/or sodium glutamate.

4. The formulation of any one or claims 1-3, wherein the VEGF receptor fusion protein:
(i) comprises two polypeptides that comprise (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2;
(ii) comprises two polypeptides that comprise an immunoglobin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of a VEGFR2, and a multimerizing component;
(iii) comprises two polypeptides that comprise an immunoglobin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of VEGFR2, an Ig domain 4 of VEGFR2 and a multimerizing component; or
(iv) comprises two VEGFR1R2-FcΔC1(a) polypeptides encoded by the nucleic acid sequence of SEQ ID NO:1.

5. The formulation of any one or claims 1-4, wherein the VEGF receptor fusion protein is selected from the group consisting of: aflibercept and conbercept.

6. The formulation of any one of claims 1-5 wherein the VEGF receptor fusion protein is aflibercept.

7. The formulation of any one of claims 1-6, wherein the VEGF receptor fusion protein is at a concentration of:

- 100 mg/ml;

- 111.5 mg/ml;
- 112.0 mg/ml;
- 113.3 mg/ml;
- 114.3 mg/ml;
- 115.6 mg/ml;
- 116.3 mg/ml;
- 120 mg/ml;
- 133 mg/ml;
- 140 mg/ml;
- 150 mg/ml;
- 200 mg/ml;
- 250 mg/ml; or
- that which contains 8 mg VEGF receptor fusion protein in 70 µl.

8. The formulation of any one of claims 1-7 wherein:
(i) the osmolality is 299 to 506 mmol/Kg; and/or
(ii) the viscosity is from 6-15 cP at 20^{o}C.

9. The formulation of any one of claims 1-8 wherein the pH is 5.8 to 6.5.

10. The formulation of claim 9 wherein the pH is 5.8.

11. The formulation of any one of claims 1-10, wherein the surfactant is a non-ionic surfactant.

12. The formulation of claim 11, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350 and mixtures thereof.

13. The formulation of any one of claims 1-12, wherein the histidine-based buffer comprises histidine hydrochloride.

14. The formulation of claim 13 comprising 10 mM to 20 mM histidine-based buffer.

15. The formulation of any one of claims 1-14, wherein the sugar is sucrose.

16. The formulation of any one of claims 1-14, wherein the sugar is mannitol, sorbitol or trehalose.

17. The formulation of any one of claims 15-16 comprising 2.5% (w/v), 5% (w/v), 8% (w/v), 10% (w/v) or 20% (w/v) sugar, which is sucrose, mannitol, sorbitol or trehalose.

18. The formulation of any one of claims 1-17 comprising surfactant at a concentration of 0.03% (w/v).

19. The formulation of any one of claims 1-18, wherein the L-arginine is L-arginine monohydrochloride.

20. The formulation of any one of claims 1-19 wherein the VEGF receptor fusion protein has less than 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to 6% high molecular weight species after storage for 24 months at 2-8^{o}C.

21. A formulation comprising the components in a formulation selected from the group consisting of:

Formulation XX: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;
Formulation ZZ: 140 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;
Formulation CCC: 80, 100, 120 or 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;
Formulation OOO: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium Citrate; 50 mM arginine hydrochloride;
Formulation PPP: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50mM glycine; 50 mM arginine hydrochloride;
Formulation QQQ: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM arginine hydrochloride;
Formulation RRR: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM arginine hydrochloride;

Formulation SSS: 140 mg/ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride;
Formulation TTT: 140 mg/ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride;
Formulation DDDD: 80.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation EEEE: 120.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation FFFF: 113.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation GGGG: 114.3 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation HHHH: 100.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation IIII: 133.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation JJJJ: 150 mg/ml aflibercept, 10 mM sodium phosphate, 8% (w/v) sucrose, 0.03% (w/v) polysorbate 20 and 50 mM arginine hydrochloride, pH 6.2; and
Formulation KKKK: 114.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8.

22. The formulation of claim 21, wherein the VEGF receptor fusion protein is aflibercept or conbercept.

23. The formulation of any one of claims 21-22 wherein the VEGF receptor fusion protein has less than 3.5% high molecular weight species immediately after manufacture and

purification and/or less than or equal to 6% high molecular weight species after storage for 24 months at 2-8^{o}C.

24. A container or injection device comprising the formulation of any one of claims 1-23.

25. The container or injection device of claim 24, which is a vial, syringe, autoinjector or pre-filled syringe.

26. A method for preparing the formulation of any one of claims 1-23, comprising combining the components of said formulation into a single composition.

27. The method of claim 26, further comprising loading a volume of the formulation into a syringe.

28. A formulation which is the product of the method of any one of claims 26-27.

29. Use of a formulation of any one of claims 1-22 and 27 in the manufacture of a medicament for the treatment of an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection into an eye of the subject.

30. Use of a VEGF receptor fusion protein in a formulation of any one of claims 1-23 or 28 in the manufacture of a medicament for the treatment of an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection into an eye of the subject at a dosage of 8 mg or more of the VEGF receptor fusion protein.

31. The use of claim 30, wherein the medicament is to be administered into the eye of the subject at a dosage of 8 mg of the VEGF receptor fusion protein.

32. The use of any one of claims 30-31, wherein the formulation is to be administered via intravitreal injection.

33. The use of any one of claims 30-32, wherein the angiogenic eye disorder is age-related macular degeneration (wet), macular edema, macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal

neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy and/or proliferative diabetic retinopathy.

34. The use of any one of claims 32-33 wherein the intravitreal injection of the VEGF receptor fusion protein is to be administered at a dosage of 75 microliters or less.

35. The use of any one of claims 30-34, wherein the VEGF receptor fusion protein is contained within a formulation comprising: 5% sucrose; a histidine buffer; and 0.03% surfactant.

36. The use of any one or claims 32-35 wherein the medicament is to be administered via intravitreal injection of the VEGF receptor fusion protein once every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 weeks.